These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 1606998)

  • 1. Adverse event monitoring in clinical trials of felodipine and omeprazole.
    Wallander MA; Lundborg P; Svärdsudd K
    Eur J Clin Pharmacol; 1992; 42(5):517-22. PubMed ID: 1606998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The way towards adverse event monitoring in clinical trials.
    Wallander MA
    Drug Saf; 1993 Mar; 8(3):251-62. PubMed ID: 8452665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
    Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
    MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety experience from long-term treatment with omeprazole.
    Joelson S; Joelson IB; Lundborg P; Walan A; Wallander MA
    Digestion; 1992; 51 Suppl 1():93-101. PubMed ID: 1397750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of three methods of symptom reporting in a clinical trial of felodipine.
    Wallander MA; Dimenäs E; Svärdsudd K; Wiklund I
    Eur J Clin Pharmacol; 1991; 41(3):187-96. PubMed ID: 1748134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies.
    Martin RM; Dunn NR; Freemantle S; Shakir S
    Br J Clin Pharmacol; 2000 Oct; 50(4):366-72. PubMed ID: 11012560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacodynamic and pharmacokinetic profiles of controlled-release formulations of felodipine and metoprolol in free and fixed combinations in elderly hypertensive patients.
    McLay JS; MacDonald TM; Hosie J; Elliott HL;
    Eur J Clin Pharmacol; 2000 Nov; 56(8):529-35. PubMed ID: 11151741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prescription-event monitoring and reporting of adverse drug reactions.
    Heeley E; Riley J; Layton D; Wilton LV; Shakir SA
    Lancet; 2001 Dec; 358(9296):1872-3. PubMed ID: 11741629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Common data elements for secondary use of electronic health record data for clinical trial execution and serious adverse event reporting.
    Bruland P; McGilchrist M; Zapletal E; Acosta D; Proeve J; Askin S; Ganslandt T; Doods J; Dugas M
    BMC Med Res Methodol; 2016 Nov; 16(1):159. PubMed ID: 27875988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical safety of omeprazole.
    Sölvell L
    Digestion; 1990; 47 Suppl 1():59-63; discussion 76. PubMed ID: 2093017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Smallpox vaccination and adverse reactions. Guidance for clinicians.
    Cono J; Casey CG; Bell DM;
    MMWR Recomm Rep; 2003 Feb; 52(RR-4):1-28. PubMed ID: 12617510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Recording and reporting adverse reactions in clinical trials. New legal provisions according to the 12th Law Amending the German Drug Law (AMG) and the Ordinance on GCP (GCP-V)].
    Eckhardt K; Cremer-Schaeffer P; König J; Paeschke N
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Feb; 48(2):173-80. PubMed ID: 15726458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of unexpected and toxic effects of omeprazole (Mopral) reported to the regional centers of pharmacovigilance during the first 22 postmarketing months].
    Castot A; Bidault I; Dahan R; Efthymiou ML
    Therapie; 1993; 48(5):469-74. PubMed ID: 8146827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dealing with a deluge of data: an assessment of adverse event data on North Central Cancer Treatment Group trials.
    Mahoney MR; Sargent DJ; O'Connell MJ; Goldberg RM; Schaefer P; Buckner JC
    J Clin Oncol; 2005 Dec; 23(36):9275-81. PubMed ID: 16361625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of serious adverse events reporting to academic sponsors of clinical trials: far from optimal.
    Crépin S; Villeneuve C; Merle L
    Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):719-24. PubMed ID: 26887649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety profile of omeprazole. Adverse events with short-term treatment.
    Nelis GF
    Digestion; 1989; 44 Suppl 1():68-76. PubMed ID: 2691312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The long-term antihypertensive efficacy and safety of a new felodipine-metoprolol combination tablet. The Swedish/UK and German Study Groups.
    Hosie J; Dahlöf B; Klein G
    Blood Press Suppl; 1993; 1():46-50. PubMed ID: 8173690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants of headache in lansoprazole users in The Netherlands: results from a nested case-control study.
    Claessens AA; Heerdink ER; van Eijk JT; Lamers CB; Leufkens HG
    Drug Saf; 2002; 25(4):287-95. PubMed ID: 11994030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension.
    Goldberg AI; Dunlay MC; Sweet CS
    Am J Cardiol; 1995 Apr; 75(12):793-5. PubMed ID: 7717281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surveillance for poliovirus vaccine adverse events, 1991 to 1998: impact of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine.
    Wattigney WA; Mootrey GT; Braun MM; Chen RT
    Pediatrics; 2001 May; 107(5):E83. PubMed ID: 11331733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.